Viridian Therapeutics, Inc.

Historical 13F Holders

Symbol
VRDN
CUSIP
92790C104
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 92790C104 since 12/18/2024, largest first.

Filer % of Class Filed
Fairmount Funds Management LLC 13D/A
14.0% 5/13/2026
Event 5/11/2026
Paradigm Biocapital Advisors LP 13G/A
7.3% 11/16/2026
Event 9/30/2026
Bellevue Group AG 13G
6.6% 5/15/2026
Event 3/31/2026
Kynam Capital Management, LP 13G/A
5.7% 8/14/2026
Event 6/30/2026
Point72 Asset Management, L.P. 13G
5.0% 8/20/2026
Event 8/19/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (6)
Price T Rowe Associates Inc /MD/ 13G/A 4.5% 11/16/2026
Event 9/30/2026
Venrock Healthcare Capital Partners III, L.P. 13G/A
4.5% 2/14/2025
Event 12/31/2024
State Street Corp 13G 4.3% 11/10/2026
Event 9/30/2026
Commodore Capital LP 13G/A
3.9% 11/14/2025
Event 9/30/2025
Deep Track Capital, LP 13G/A
3.3% 8/14/2026
Event 6/30/2026
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 236 137 M $2.83B
2026 Q2 220 136 M $2.50B
2026 Q1 228 112 M $2.21B
2025 Q4 231 108 M $3.36B
2025 Q3 170 93.2 M $2.01B
2025 Q2 174 94.6 M $1.32B
2025 Q1 180 91.4 M $1.23B
2024 Q4 182 91.0 M $1.75B
2024 Q3 170 87.0 M $1.98B
2024 Q2 143 69.7 M $906M
2024 Q1 141 71.0 M $1.24B
2023 Q4 136 60.2 M $1.31B
2023 Q3 125 50.2 M $770M
2023 Q2 134 47.1 M $1.12B
2023 Q1 140 43.1 M $1.10B
2022 Q4 125 41.3 M $1.21B
2022 Q3 106 38.0 M $778M
2022 Q2 90 28.3 M $328M
2022 Q1 76 24.9 M $461M
2021 Q4 59 23.3 M $460M
2021 Q3 43 13.6 M $224M
2021 Q2 27 6.00 M $110M
2021 Q1 34 5.54 M $84.5M
2020 Q4 2 229 k $3.77M